Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Company Deals

Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate

Fineline Cube Feb 10, 2026
Company Deals

GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing

Fineline Cube Feb 10, 2026
Company Deals

Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million

Fineline Cube Feb 10, 2026
Company Deals

Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Deals

Sanyou Bio and FatiAbGen Forge AI-STAL Alliance for Korea and Global Markets

Fineline Cube Dec 1, 2025

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and South Korea’s FatiAbGen Co., Ltd. announced a comprehensive strategic...

Company Drug

Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND

Fineline Cube Dec 1, 2025

Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP‑1R/GIPR/GCGR...

Company Drug

Mabwell’s 9MW1911 Cuts COPD Exacerbations by 30% in Phase 2a, FDA Accepts US Trial Application

Fineline Cube Dec 1, 2025

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its ST2‑blocking monoclonal antibody 9MW1911 has...

Company Deals Drug

Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR‑T Combination for Advanced Solid Tumors

Fineline Cube Dec 1, 2025

Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co‑development...

Company Deals

Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech

Fineline Cube Dec 1, 2025

Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New...

Company Drug

iRegene’s NouvNeu004 Wins FDA Special Exemption for MSA Cell Therapy

Fineline Cube Dec 1, 2025

iRegene Therapeutics announced that the U.S. FDA granted Special Exemption status to NouvNeu004 injection, approving...

Company Deals

Proviva’s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost

Fineline Cube Dec 1, 2025

Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD 30 million led...

Company Drug

Pfizer-Astellas’ PADCEV Wins FDA Approval for Perioperative Bladder Cancer

Fineline Cube Nov 29, 2025

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food...

Company Drug

GenSci’s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials

Fineline Cube Nov 29, 2025

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci...

Company Drug

Jiuzhou Pharmaceutical Wins Tentative FDA Approval for Generic Janumet XR

Fineline Cube Nov 28, 2025

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (SHA: 603456) announced that its Abbreviated New Drug Application (ANDA)...

Company Drug

Hengrui’s Ivarmacitinib Wins NMPA Nod for Vitiligo Clinical Trials

Fineline Cube Nov 28, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that Ivarmacitinib Tablets and SHR0302...

Company Drug

Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise

Fineline Cube Nov 28, 2025

Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China’s first self‑developed CD19‑targeting CAR‑T...

Company Drug

Innovent’s Picankibart Wins NMPA Approval for Psoriasis as IL-23p19 Inhibitor

Fineline Cube Nov 28, 2025

Innovent Biologics, Inc. (HKG: 1801) announced that Picankibart Monoclonal Antibody Injection (IBI112), branded XINMEIYUE, received...

Company Deals

Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation

Fineline Cube Nov 28, 2025

Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB...

Company Drug

Boan Biotech’s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases

Fineline Cube Nov 27, 2025

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self‑developed Aflibercept Intravitreal Injection (Boyoujing)...

Company Deals

Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront

Fineline Cube Nov 27, 2025

Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc....

Company Drug

Novo Nordisk’s Semaglutide 7.2 mg sNDA Submitted for Weight Management

Fineline Cube Nov 27, 2025

Novo Nordisk A/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA)...

Company Drug

CSPC’s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management

Fineline Cube Nov 27, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self‑developed recombinant fully human anti‑ActRIIA/IIB monoclonal...

Company Medical Device

MicroTech’s LinX CGM Wins India Approval, Expanding Asia Diabetes Monitoring

Fineline Cube Nov 27, 2025

MicroTech Medical (Hangzhou) Co., Ltd. (HKG: 2235) announced that its LinX Continuous Glucose Monitoring (CGM)...

Medical Device

Bio-heart’s IberiRDN Wins New Zealand Nod as Only Dual-Approach Renal Denervation System

Fineline Cube Nov 27, 2025

Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced that its Iberis Multi-Electrode Renal Denervation...

Posts pagination

1 … 30 31 32 … 622

Recent updates

  • Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development
  • Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent
  • Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate
  • GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing
  • Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Company Digital

Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent

Company Deals

Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate

Company Deals

GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.